Does Metformin Benefit The Risk And Survival Of Lung Cancer In T2DM Patients .pdf
Original filename: Does Metformin Benefit The Risk And Survival Of Lung Cancer In T2DM Patients.pdf
This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 13/08/2020 at 10:44, from IP address 218.76.x.x.
The current document download page has been viewed 34 times.
File size: 237 KB (4 pages).
Privacy: public file
Download original PDF file
Does Metformin Benefit The Risk
And Survival Of Lung Cancer In
Metformin, marketed under the trade name Glucophage, is the first-line
medication for the treatment of type 2 diabetes, particularly in people who are
overweight. Metformin is a biguanide antihyperglycemic agent. It works by
decreasing glucose production by the liver, by increasing the insulin sensitivity
of body tissues, and by exerting an anorexiant effect, thereby reducing caloric
The results of a newly published meta-analysis study showed that metformin
may reduce the risk of lung cancer in patients with type 2 diabetes by 22%, and
in Asian populations this value can reached to 34%. In addition, for patients
with type 2 diabetes who have already suffered from lung cancer, metformin
can increase the survival rate of patients by 35% significantly.
Metformin is the first-line drug for the treatment of type 2 diabetes (T2DM) and
it has been widely used in clinical practice. Tumor proliferation and progression
are increased in patients with cancer complicated with T2DM due to increased
levels of hyperinsulinemia, hyperglycemia, and inflammatory cytokines. In
recent years, studies have found that metformin has a certain anti-cancer
effect. Does metformin benefit the risk and survival of lung cancer in T2DM
Current studies believe that metformin plays an anticancer role mainly by
activating AMPK and inhibiting protein synthesis. In clinical practice, it has been
found that in patients with ovarian cancer with T2DM, taking metformin after
diagnosis is associated with improved overall survival and progression-free
survival. Similar results have been found in studies of colorectal
cancer. However, it was found that taking metformin had no significant effect in
prostate cancer or breast cancer. The relationship between metformin and the
prevalence and survival rate of lung cancer is controversial.
To explore this issue, Chinese researchers conducted a meta-analysis on the
"The effect of metformin on lung cancer risk and survival in patients with type 2
diabetes mellitus: A meta‐analysis", and the results of the study were
published in the journal Clinical Pharmacy and Therapeutics.
Metformin can reduce lung cancer risk in patients with T2DM
In the meta-analysis of all eight studies, T2DM patients treated with metformin
had a 22% reduction in lung cancer risk compared with T2DM patients treated
without metformin (HR=0.78，95%CI 0.70-0.86；P＜0.00001).
Picture 1 research result
In 4 studies of Asian patients, it was observed that metformin had a significant
preventive effect on lung cancer (HR=0.66, 95%CI 0.56-0.76; P<0.00001), but
this significant effect was not observed in the four European patients (HR=0.90,
95%CI 0.78-1.03; P=0.12) (Table 1).
Table 1 Effect of metformin on the risk of lung cancer in patients with T2DM in Asia/Europe
Metformin can increase lung cancer survival rate in patients
with T2DM by 35%
In the analysis of all 10 studies, metformin use was significantly associated with
a 35% increase in overall survival in lung cancer patients (HR=0.65, 95%CI
0.55-0.77;P < 0.00001).
Picture 2 research result
In 5 studies on Asian patients (HR=0.57, 95%CI 0.49-0.66;P < 0.00001) and 5
studies on non-Asian patients (HR=0.79, 95%CI 0.71-0.88;In P < 0.0001),
metformin was observed to significantly improve the survival rate of lung cancer
in T2DM patients.
In the histology of lung cancer, there is also a significant correlation between
the use of metformin and the survival rate. In 7 studies on patients with
non-small cell lung cancer (NSCLC) (HR=0.68, 95%CI 0.54-0.84; P=0.0004)
and 2 studies on patients with small cell lung cancer (SCLC) (HR=0.52, 95%) In
CI 0.39-0.69; P<0.00001), the metformin group showed significant benefits
Table 2 Effect of metformin on the survival in patients with T2DM lung cancer
The results of this study showed that metformin could reduce the risk of lung
cancer in patients with T2DM and improve the survival rate. Its protective effect
on Asian patients was clear. This study has some implications for the clinical
treatment of patients with T2DM with lung cancer.
T2DM, formerly known as adult-onset diabetes, is a form of diabetes that is
characterized by high blood sugar, insulin resistance, and relative lack of insulin.
Besides metformin, semaglutide and liraglutide are two common drugs which
also used to treat type 2 diabetes. Huateng Pharma, a leading pharmaceutical
company focusing on R&D of pharmaceutical intermediates, we provide
Anti-Diabetic intermediates such as semaglutide
intermediates and liraglutide intermediates with high purity.
 The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes
mellitus: A meta‐analysis
 Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy
 The things you need to know about diabetes
 Novo Nordisk's Semaglutide Shows Promise in Weight Loss
 Semaglutide : First Oral GLP-1 Treatment for Type 2 Diabetes
 Antidiabetic Drugs Classification and Mechanism of Action